India's Lupin again recalling meds made with failed ingredient

1

India’s Lupin is recalling products again, and again it is for having manufactured drugs with an ingredient that failed specifications.

After recently having to recall nearly 54,000 vials of an antibiotic made at its plant in Mandideep, India, the drugmaker is now recalling nearly 86,000 bottles of blood pressure meds manufactured at a plant in Pithampur, according to the latest FDA Enforcement Report.  

The drugmaker is recalling 59,520 bottles of the combo drug lisinopril and hydrochlorothiazide. It also is recalling 26,467 bottles of lisinopril tablets. Classified this week by the FDA, the company actually began the recall in April.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

This retrieval comes on the heels of Lupin’s recall of 53,902 vials of injected ceftriaxone. In that case, the drugs were manufactured at a plant that Lupin had disclosed in March had received a Form 483 following an FDA inspection.

Lupin last year also received a Form 483 with 9 observations for a plant in Goa, and the year before the FDA cited a facility in Indore with half a dozen.

The recalls come as Lupin is trying hard to increase its market share in the U.S. Earlier this year it laid out $900 million to buy New Jersey-based Gavis Pharmaceuticals, getting a 45,000-square-foot manufacturing and R&D site and a 124,000-square-foot packaging and distribution operation in Somerset, NJ, as part of the deal. It also got a portfolio of 120 marketed products and 62 ANDA filings.

- access the recalls here

Related Articles: 
Lupin recalling antibiotic produced at plant cited by FDA 
FDA cites Lupin Indian facilities for what drugmaker calls 'minor' issues 
Lupin gets first U.S. manufacturing base with buyout of GAVIS

Read more on

Suggested Articles

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.